12701 Commonwealth Drive
199 articles with NeoGenomics, Inc.
NeoGenomics, Inc. announced today that it plans to release its second quarter 2020 financial results on Tuesday, July 28, 2020
NeoGenomics, Inc., a leading provider of cancer-focused genetic testing services, announced that it plans to release its second quarter 2020 financial results on Tuesday, July 28, 2020.
FT. MYERS, FL / ACCESSWIRE / July 1, 2020 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services, announced today that it plans to release its second quarter 2020 financial results on Tuesday, July 28, 2020. The Company has scheduled a web-cast and conference call to discuss their first quarter results on Tuesday, July 28, 2020 at 8:30 AM EDT.
Bayer and NeoGenomics Launch the Test4TRK™ Program to Provide Genomic Cancer Testing at No Cost for People Living with Advanced Thyroid and Colorectal Cancers
Bayer to cover testing costs for patients with RAI-refractory (RAI-R) differentiated thyroid carcinoma (DTC) and metastatic colorectal cancer (mCRC) with high microsatellite instability (MSI-H) The results of a genomic cancer test can help healthcare providers determine appropriate treatment plans for people with an NTRK gene fusion NTRK gene fusions can drive tumor growth and are more common in MSI-H mCRC and RAI-R DTC cases than other subt
QIAGEN and NeoGenomics collaborate to offer cancer patients Day-One access to innovative companion diagnostics for newly approved drugs
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) and NeoGenomics, Inc. (NASDAQ: NEO) today announced a master service agreement to accelerate the availability of innovative companion diagnostics that enable precision medicine for cancer patients
NeoGenomics Europe S.A. Opens Its Doors in Rolle, Switzerland Laboratory Hosting Business Leaders, Dignitaries and Local Government Officials
NeoGenomics opened the doors of its new Rolle, Switzerland facility on Wednesday, November 8th to bring its unique Pharma Services offering to the global research community.
NeoGenomics Announces the Opening of Its First International Laboratory near Geneva, Switzerland to Support Clinical Trials
NeoGenomics Announces the Opening of its First International Laboratory near Geneva, Switzerland to Support Clinical Trials FT. MYERS, FL--(Marketwired - October 24, 2017) - NeoGenomics, Inc. ( NASDAQ : NEO ) , a leading provider of cancer-focused genetic testing services in the United States, announced today that it has opened its first international laboratory facility in Rolle, Switzerland, in the Canton of Vaud, just outside of Geneva as a separate subsidiary, NeoGenomics Euro
NeoGenomics Reports Record Revenue Of $66.1 Million On 16% Volume Growth And 13% Reduction In Average Cost Per Test In The Second Quarter Of 2017
NeoGenomics And Definiens AG Enter Into Agreement To Develop Novel Assays For Clinical Trials & Clinical Testing
NeoGenomics Reports 142% Revenue Growth To $60.8 Million And A Record $9.6 Million In Cash Flow From Operations In The Third Quarter Of 2016
NeoGenomics Reports 159% Revenue Growth To $63.1 Million And Strong Gains In Profitability In The Second Quarter Of 2016
NeoGenomics Reports 159% Revenue Growth To $59.7 Million And 442% Adjusted EBITDA Increase To $8.2 Million, Driven By Clarient Acquisition And Strong Volume Gains
NeoGenomics Reports Record Revenue Of $27.2 Million And Record Adjusted EBITDA Of $2.9 Million In Fourth Quarter, Driven By Strong Volume Gains
NeoGenomics Launches New Liquid Biopsy Tests For Monitoring Solid Tumors And Predicting Resistance To BTK Inhibitors